Trials and research

Myeloproliferative neoplasms (MPNs) are rare blood cancers which were classed as a family by William Dameshek in 1951 and although doctors could give a diagnosis and offer treatment, no one really knew the mechanisms behind these illnesses. Discovering the JAK2 V617F mutation was a major breakthrough in the understanding of MPNs and in many ways has triggered a tsunami of research and important data in this field.

For patients however, the choice and terminology surrounding the whole area of trials and research may be confusing so we have tried to summarise what’s involved.